Holen Sie sich die Stockscreener-App
116.20
0.21%
-0.265
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com Canada
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - The Globe and Mail
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - Investing News Network
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media
KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria
Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Wellington Management Group LLP Trims Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
119,503 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by The Manufacturers Life Insurance Company - MarketBeat
Freestone Grove Partners LP Purchases New Shares in Kymera Therapeutics, Inc. $KYMR - MarketBeat
20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY - MarketBeat
Kymera Therapeutics Inc. (KYMR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Wells Fargo & Company Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 149,908 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC - MarketBeat
Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc. - MarketBeat
Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
B of A, Truist raise Kymera Therapeutics price targets - scanx.trade
Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE - MarketBeat
Kymera Therapeutics (KYMR) Advances 3.42% to $121.41 as Protein Degradation Platform Gains Investor AttentionAnalyst Upgrade Stocks - vinanet.vn
Kymera Therapeutics Inc (KYMR) (Q2 2026) Earnings Call Highlight - GuruFocus
Kymera Therapeutics Stock Rockets 17% With 9-Day Winning Streak - Trefis
A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% - Trefis
State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Edges Higher by 1.4% as Shares Test Key Resistance at $121.87IV Spike - Vinanet
T. Rowe Price Associates (KYMR) reports 8.6% stake in Kymera Therapeutics - Stock Titan
Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14% - Trefis
A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14% - Trefis
Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics - Stock Titan
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132 - Moomoo
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):